329055-23-4|Irbesartan HCl|1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- hydrochloride|-范德生物科技公司

Irbesartan HCl

NMR下载 COA and HPLC MSDS下载
names：
1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- hydrochloride
CAS号：
329055-23-4
MDL Number：
MF(分子式)： C25H29ClN6O MW(分子量)： 464.998
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Irbesartan HCl
英文别名	Irbesartan HCl; Irbesartan hydrochloride; Irbesartan, Avapro, Aprovel, Karvea, BMS-186295; BMS 186295; BMS186295;
CAS号	329055-23-4
SMILES	O=C1N(CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)C(CCCC)=NC15CCCC5.[H]Cl
Inchi	InChI=1S/C25H28N6O.ClH/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23;/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30);1H
InchiKey	ZUYFSRQJPNUOQU-UHFFFAOYSA-N
分子式 Formula	C25H29ClN6O
分子量 Molecular Weight	464.998
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Irbesartan HCl(CAS:329055-23-4 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Irbesartan, also known as BMS-186295, is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Zhang F, Zhou G, Guo L, Lu F, Zhou G. Comparison of clinical efficacy of metoprolol combined with irbesartan and hydrochlorothiazide and non-invasive ventilator in the emergency treatment of patients with severe heart failure. Exp Ther Med. 2018 Dec;16(6):5059-5066. doi: 10.3892/etm.2018.6828. Epub 2018 Oct 4. PubMed PMID: 30542460; PubMed Central PMCID: PMC6257578.

[2]Ashour S, Bayram R. Selective and validated kinetic spectrophotometric method for the determination of irbesartan in pure and pharmaceutical formulations. Ann Pharm Fr. 2018 Nov 21. pii: S0003-4509(18)30114-7. doi: 10.1016/j.pharma.2018.09.002. [Epub ahead of print] PubMed PMID: 30471775.

[3] Hoffmann M, Chen X, Hirano M, Arimitsu K, Kimura H, Higuchi T, Decker M. (18) F-Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging. ChemMedChem. 2018 Dec 6;13(23):2546-2557. doi: 10.1002/cmdc.201800638. Epub 2018 Nov 15. PubMed PMID: 30430750.

[4] Li T, Yao W. Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. Exp Ther Med. 2018 Nov;16(5):4119-4123. doi: 10.3892/etm.2018.6669. Epub 2018 Aug 30. PubMed PMID: 30402154; PubMed Central PMCID: PMC6200972.

[5] Boccellino M, Di Domenico M, Donniacuo M, Bitti G, Gritti G, Ambrosio P, Quagliuolo L, Rinaldi B. AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress. PLoS One. 2018 Oct 24;13(10):e0202297. doi: 10.1371/journal.pone.0202297. eCollection 2018. PubMed PMID: 30356256; PubMed Central PMCID: PMC6200178.

6: Mohamed EA, Ahmed HI, Zaky HS. Protective effect of irbesartan against doxorubicin-induced nephrotoxicity in rats: implication of AMPK, PI3K/Akt, and mTOR signaling pathways. Can J Physiol Pharmacol. 2018 Dec;96(12):1209-1217. doi: 10.1139/cjpp-2018-0259. Epub 2018 Oct 23. PubMed PMID: 30351976.7: Hu S, Cheng J, Weinstock J, Fan X, Venners SA, Hsu YH, Suwen Wu, Pan F, Zha X, Sun J, Jiang S, Xu X. A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension. J Hum Hypertens. 2018 Nov;32(11):781-788. doi: 10.1038/s41371-018-0119-1. Epub 2018 Oct 3. PubMed PMID: 30283089.8: Bikos A, Loutradis C, Aggeloudi E, Karpetas A, Raptis V, Kalaitzidis R, Panagoutsos S, Pasadakis P, Balaskas I, Liakopoulos V, Papagianni A, Sarafidis PA. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study. J Hypertens. 2018 Jul 30. doi: 10.1097/HJH.0000000000001891. [Epub ahead of print] PubMed PMID: 30063644.9: Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. PubMed PMID: 30002098.10: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501626/ PubMed PMID: 30000687.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开